NASDAQ: TKNOAlpha Teknova Inc Stock
$2.00+0.00 (+0%)
Updated Apr 22, 2024
TKNO Price
$2.00
Fair Value Price
N/A
Market Cap
$81.65M
52 Week Low
$1.62
52 Week High
$4.27
P/E
-1.72x
P/B
0.91x
P/S
3.24x
PEG
N/A
Dividend Yield
N/A
Revenue
$36.68M
Earnings
-$36.78M
Gross Margin
28.1%
Operating Margin
-98.8%
Profit Margin
-100.3%
Debt to Equity
0.43
Operating Cash Flow
-$19M
Beta
1.32
Next Earnings
May 8, 2024
Ex-Dividend
N/A
Next Dividend
N/A
TKNO Overview
Alpha Teknova Incorporated provides reagents to pharmaceutical and biotechnology companies as well as academic and government research institutions in the U.S. and internationally. Reagents facilitate the discovery, development, and production of biopharmaceutical products (drug therapies and vaccines) and molecular diagnostics. It also offers contract development and manufacturing services and in vitro diagnostic franchises. Alpha Teknova was founded in 1996 and is headquartered in Hollister, CA.
Zen Score
–
Industry Average (25)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how TKNO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
TKNO is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
TKNO is good value based on its book value relative to its share price (0.91x), compared to the US Drug Manufacturers - Specialty & Generic industry average (2.04x)
P/B vs Industry Valuation
TKNO is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more TKNO due diligence checks available for Premium users.
Be the first to know about important TKNO news, forecast changes, insider trades & much more!
TKNO News
Valuation
TKNO fair value
Fair Value of TKNO stock based on Discounted Cash Flow (DCF)
Price
$2.00
Fair Value
$4.27
Undervalued by
53.19%
TKNO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
TKNO price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.72x
Industry
46.47x
Market
41x
TKNO price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.91x
Industry
2.04x
TKNO is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
TKNO's financial health
Profit margin
Revenue
$7.9M
Net Income
-$10.7M
Profit Margin
-135.5%
TKNO's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
TKNO's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$128.6M
Liabilities
$38.6M
Debt to equity
0.43
TKNO's short-term assets ($45.66M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
TKNO's short-term assets ($45.66M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
TKNO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.9M
Investing
-$115.0k
Financing
-$621.0k
TKNO's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
TKNO vs Pharmaceutical Stocks
Alpha Teknova Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.